Better vaccines for tuberculosis could save millions of lives

Cases of one of the world's deadliest diseases—tuberculosis—are rising at an alarming rate, despite widespread vaccination. Reasons for the ineffectiveness of the vaccine, especially in regions where this infectious disease is endemic, as well as arguments for replacing the existing vaccine with novel synthetic vaccines, are presented in a review published online August 28th in Trends in Molecular Medicine.

"Tuberculosis is a global , and it is a highly communicable disease that may influence practically anyone and everyone," says senior author Javed Agrewala of the CSIR-Institute of Microbial Technology in Chandigarh, India. "There is a serious need and challenge for the scientific community to develop alternative vaccination approaches for the control of the disease."

Tuberculosis is a caused by Mycobacterium tuberculosis (Mtb). About one third of the world's population is infected with Mtb, which causes about two million deaths each year. Vaccines may be the best strategy for controlling tuberculosis, but the only available vaccine—Bacillus Calmette-Guerin (BCG)—does not reliably prevent the disease in adults, especially in regions where tuberculosis is endemic.

In the review, Agrewala explains that BCG does not work well in these regions because exposure to prevalent mycobacterial strains triggers the production of antibodies that counteract the vaccine. In addition, infections with called helminths interfere with protective immune responses induced by BCG.

To overcome these limitations, Agrewala proposes the use of novel vaccines called lipidated-promiscuous-peptide vaccines. These synthetic vaccines are safer than BCG because they do not contain infectious material. Moreover, they generate long-lasting, protective immune responses and are not influenced by pre-existing antibodies. This type of vaccine strategy has already proven to be successful in an of tuberculosis and is being tested in human clinical trials for other infectious diseases and cancer.

"We believe that lipidated-promiscuous-peptide vaccines have all the essential qualities that can make them successful in tuberculosis-endemic countries," Agrewala says. "Such vaccines can impart better protection than and will have a long-reaching positive impact on millions of people."

More information: Gowthama et al. "Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions" dx.doi.org/10.1016/j.molmed.2012.07.008

add to favorites email to friend print save as pdf

Related Stories

Scientists find candidate for new TB vaccine

Mar 18, 2011

Scientists have discovered a protein secreted by tuberculosis (TB) bacteria that could be a promising new vaccine candidate, they report today in Proceedings of the National Academy of Sciences. The protein could also be use ...

Tuberculosis vaccine being tested in Phase II trial

Mar 26, 2012

The only tuberculosis vaccine currently available is already over 90 years old - and is unsatisfactory in terms of its effectiveness. Although it protects young children against developing tuberculosis, it ...

Recommended for you

World 'losing the battle' to contain Ebola: MSF

10 minutes ago

International medical agency Medecins sans Frontieres said Tuesday the world was "losing the battle" to contain Ebola and called for a global biological disaster response to get aid and personnel to west Africa.

Mutating Ebola viruses not as scary as evolving ones

40 minutes ago

My social media accounts today are cluttered with stories about "mutating" Ebola viruses. The usually excellent ScienceAlert, for example, rather breathlessly informs us "The Ebola virus is mutating faster in humans than in animal hosts ...

War between bacteria and phages benefits humans

1 hour ago

In the battle between our immune systems and cholera bacteria, humans may have an unknown ally in bacteria-killing viruses known as phages. In a new study, researchers from Tufts University, Massachusetts ...

Ebola kills 31 people in DR Congo: WHO

3 hours ago

An outbreak of the Ebola virus in the Democratic Republic of Congo has killed 31 people and the epidemic remains contained in a remote northwestern region, UN the World Health Organization (WHO) said Tuesday.

Dengue fever strikes models in Japan

5 hours ago

A worsening outbreak of dengue fever in Japan has claimed its first celebrities—two young models sent on assignment to the Tokyo park believed to be its source.

Japanese researchers develop 30-minute Ebola test

5 hours ago

Japanese researchers said Tuesday they had developed a new method to detect the presence of the Ebola virus in 30 minutes, with technology that could allow doctors to quickly diagnose infection.

User comments